Glasdegib Maleate

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, City of Hope Medical Center

Conditions

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Phase 1

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

CompletedNCT03390296

M.D. Anderson Cancer CenterRecurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Start: 2017-12-27End: 2022-02-04Updated: 2023-09-05

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

WithdrawnNCT04655391

City of Hope Medical CenterRecurrent Acute Myeloid Leukemia

Start: 2022-06-25End: 2023-12-15Updated: 2022-06-09

Related Papers

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

Leukemia & lymphoma/Leukemia and lymphoma2022-04-2023 citations

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions

HemaSphere2021-06-0112 citations